We can’t show the full text here under this license. Use the link below to read it at the source.
Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: A model‐based approach
Changes in blood sugar control and body weight after switching to semaglutide from other similar diabetes drugs
AI simplified
Abstract
Switching from another GLP-1 receptor agonist to semaglutide may lead to reductions of ~0.3% to ~0.8%-points in and ~2% to ~4% in body weight with semaglutide 1.0 mg.
- The potency-adjusted total effective GLP-1RA concentration increased after switching treatments.
- Temporary slight deteriorations in HbA1c were noted when switching to semaglutide 0.25 mg.
- Switching to semaglutide from liraglutide, dulaglutide, or exenatide extended-release is associated with further reductions in HbA1c and body weight.
- Higher initial doses of semaglutide may prevent initial deterioration in outcomes.
AI simplified
Key numbers
~0.3% to ~0.8%
Reduction Range
Predicted reductions in after switching to semaglutide 1.0 mg.
~2% to ~4%
Body Weight Reduction Range
Predicted reductions in body weight after switching to semaglutide 1.0 mg.